Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Overkamp

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2021
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 statusAlexander Hein, Andreas D Hartkopf, Julius Emons, et al.
Geburtshilfe Und Frauenheilkunde|August 29, 2017
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryMarkus Wallwiener, Felix Heindl, Sara Y Brucker, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Breast (Edinburgh, Scotland)|January 8, 2021
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2021
Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on PrognosisPeter A Fasching, Siddhartha Yadav, Chunling Hu, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2021
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 statusAlexander Hein, Andreas D Hartkopf, Julius Emons, et al.
Geburtshilfe Und Frauenheilkunde|August 29, 2017
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryMarkus Wallwiener, Felix Heindl, Sara Y Brucker, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Breast (Edinburgh, Scotland)|January 8, 2021
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2021
Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on PrognosisPeter A Fasching, Siddhartha Yadav, Chunling Hu, et al.
Pageof 6